Small Cap Profits.com Featured Article: (IRSB.OB)

May 12, 2010

Iris BioTechnologies, Inc. (IRSB.OB)

Iris BioTechnologies Inc., a life sciences company, announced yesterday that they received two new Canadian patents. The company now holds patents in Canada, United States and many other counries in Europe, Asia, Australia and New Zealand.  An informatics system called BioWindows™ helps the company accurately determine medical solutions to given problems. They accomplish this by categorizing individuals according to their molecular signatures and personal profiles.

One of the patents granted to Iris BioTechnologies protects the Company’s Nano-Biochip™ enabling the use of probes with superior binding affinity and specificity to undergo incorporation into the technology platform. The second patent on their BioWindows™ Informatics System enables a more effective diagnosis and targeted treatment for breast cancer, colon cancer, neurological disorders, heart disease, diabetes, and gene-related metabolic problems.

Data that Iris BioTechnologies’ Nano-Biochip™ provides, along with the patient’s medical history, family medical history, life dynamic factors, and environmental exposures, undergo storage and analysis by BioWindows™. This is to help clinicians choose the most personalized protocol for their patients.

Chief Executive Officer, Simon Chin, said, “This is an exciting time for Iris BioTechnologies as we continue building our valuable portfolio of intellectual property not only in the United States but around the world. Over the past year, we have designed and built a patent-protected, advanced chip-making system, which positions Iris in the forefront of personalized medicine. These patents protect our technologies improving our outlook for product, service, and licensing revenue streams going forward.”

Headquartered in Santa Clara, California, Iris BioTechnologies Inc.’s dedication is to creating a novel approach to monitor gene and protein activities in order to identify the ideal treatment solution for patients. The Company was the recipient of the Frost and Sullivan 2008 Technology Innovation Award in Pharmacogenomics. Iris BioTechnologies Inc.’s always growing database, in addition to their development of the BreastCancerChip™, ColonCancerChip™, ComprehensiveCancerChip™, NeuroChip™, CardioChip™, and MetabolicChip™ adds to their broad product pipeline.

Can this form of identification of the best treatment solutions for patients be the model for the future of diagnostics?  It appears to be well on its way to becoming just that.


___________________________________________________________________________